Abstract 472P
Background
Radiological part-solid nodules (PSNs) containing both solid and ground-glass opacity (GGO) component has lower incidence of nodal metastasis and better prognosis than radiological solid nodules. Previous studies demonstrated that risk of recurrence in GGO-predominant PSNs (0< consolidation-to-tumor ratio ≤0.5) was negligible, while recurrence was not rare in solid- predominant PSNs (0.5< consolidation-to-tumor ratio <1). However, the detailed recurrence patterns and the role of adjuvant therapy after recurrence remained unclear in solid-predominant PSNs.
Methods
Patients with cN0 solid-predominant PSNs (0.5< consolidation-to-tumor ratio <1) undergoing surgery from 2008 to 2015 were collected. The exclusion criteria were as follows: (a) adenocarcinoma in situ or minimally invasive adenocarcinoma, (b) history of other malignancy, (c) multiple primary lesions, and (d) positive resection margin. Median follow-up time was 77.0 months. The initial recurrence site and adjuvant treatment data were collected.
Results
This study included 443 solid-predominant PSNs. Postoperative recurrence was diagnosed in 88 patients (19.9%), including 38 (8.6%) distant, 26 (5.9%) locoregional, and 24 (5.4%) combined recurrences. Lymph node metastasis (P=0.011), lymphovascular invasion (P=0.001), and larger solid component size (P=0.007) were independent predictors of postoperative recurrence. Multivariate Cox regression identified older age (P=0.014, HR=1.044) and early recurrence (P<0.001, HR=4.046) as independent predictors of decreased survival in patients who experienced recurrence. EGFR mutation and ALK rearrangement were identified in 44 (50.0%) and 3 (3.4%) patients who experienced recurrence, respectively. Tyrosine kinase inhibitors demonstrated significant advantages over chemotherapy in patients who experienced recurrence. (median overall survival: 75 vs. 52 months, P=0.004).
Conclusions
Radiological solid-predominant PSNs comprise a heterogeneous population. Active follow-up and effective adjuvant treatment is warranted in patients with risk factors of recurrence. Patients with driver mutations can greatly benefit from targeted therapy if recurrence occurs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract